According to Quest Diagnostics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.51136. At the end of 2023 the company had a P/S ratio of 1.68.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.68 | -7.05% |
2022 | 1.80 | -8.37% |
2021 | 1.97 | 15.6% |
2020 | 1.70 | -7.43% |
2019 | 1.84 | 23.16% |
2018 | 1.49 | -16.9% |
2017 | 1.80 | 5.95% |
2016 | 1.70 | 24.88% |
2015 | 1.36 | 4.53% |
2014 | 1.30 | 20.39% |
2013 | 1.08 | -14.68% |
2012 | 1.26 | 3.68% |
2011 | 1.22 | -2.46% |
2010 | 1.25 | -15.77% |
2009 | 1.48 | 5.99% |
2008 | 1.40 | -8.56% |
2007 | 1.53 | -6.59% |
2006 | 1.64 | -11.83% |
2005 | 1.86 | -1.39% |
2004 | 1.89 | 18.89% |
2003 | 1.59 | 16.92% |
2002 | 1.36 | -28.51% |
2001 | 1.90 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
LabCorp LH | 1.30 | -13.95% | ๐บ๐ธ USA |
Translate Bio
TBIO.defunct | N/A | N/A | ๐บ๐ธ USA |
Psychemedics PMD | 0.6726 | -55.50% | ๐บ๐ธ USA |
NeoGenomics
NEO | 2.97 | 96.60% | ๐บ๐ธ USA |
Qiagen QGEN | 4.45 | 194.15% | ๐ณ๐ฑ Netherlands |
Enzo Biochem ENZ | 4.52 | 199.08% | ๐บ๐ธ USA |